Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer

Journal Article · Wed Sep 15 00:00:00 EDT 2021 · Experimental Cell Research

DOI:https://doi.org/10.1016/J.YEXCR.2021.112742· OSTI ID:23195535

Zhang, Guonan; Zhang, Jie ^[1]; Zhu, Yi ^[1]; Liu, Hong; Shi, Yu ^[1]; Mi, Kun; Li, Meiying; Zhao, Qi ^[2]; Huang, Ziyi ^[3]; Huang, Jianming ^[2]

---

1. Department of Gynecologic Oncology, Sichuan Cancer Hospital, Chengdu, 610041 (China)
2. Department of Biochemistry & Molecular Biology, Sichuan Cancer Institute, Chengdu, 610041 (China)
3. Department of Bioinformatics, Basic Medical College of Chongqing Medical University, Chongqing (China)

Highlights: • BRCA2 BRC domain-associated mutation confers higher platinum sensitivity of HGSOC. • Somatic BRCA2 BRC domain mutation impairs BRCA2 HR in HGSOC. • BRCA2 BRC domain mutation at sites is crucial for HR repair of DNA DSB induced by platinums. • Somatic BRCA2 BRC domain missense mutations improve outcomes in patients with HGSOC. Mutations at sites crucial for the interaction between RAD51 and BRC domains impair the ability of BRCA2 homologous recombination. We aimed to clarify whether BRCA2 BRC domain-associated mutation correlates with sensibility of platinum-based chemotherapy and survival in high-grade serous ovarian cancer (HGSOC).

• OSTI ID: 23195535
• Journal Information: Experimental Cell Research, Vol. 406, Issue 1; Other Information: Copyright (c) 2021 The Authors. Published by Elsevier Inc.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0014-4827
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
BIOLOGICAL REPAIR
CHEMOTHERAPY
DNA
GENE RECOMBINATION
NEOPLASMS
OVARIES
PATIENTS
PLATINUM
SENSITIVITY
SOMATIC MUTATIONS